Overview

Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment

Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This multicenter randomized controlled clinical trial was conducted to compare the eradication efficacy and health economic benefits of individualized regimens based on HP drug resistance mutation gene detection (multiple PCR method), individualized regimens based on HP traditional drug sensitivity testing (E-test method) and empirical regimens in the Helicobacter pylori treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Zhongshan Hospital
Treatments:
Amoxicillin
Bismuth
Clarithromycin
Esomeprazole
Levofloxacin
Metronidazole
Potassium Citrate
Tetracycline